2 unknown. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 3 | 2 | Unknown 2 |
Follow Insomnia Disorder: new trials by email Literature Review of Insomnia Disorder trials Research Report on Insomnia Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder. Zolpidem - Insomnia Disorder | Phase 2 / Phase 3 | Unknown | Biolab Sanus Farmaceutica | 366 | 2021-03-01 | 2020-07-27 |
| Melatonin 3mg and 5mg Compared to Cognitive Behavioral Therapy for Insomnia (CBT-I) in the Treatment of Insomnia CBT-I plus placebo, CBT-I plus Melatonin 3 mg, CBT-I plus Melatonin 5 mg - Insomnia Disorder | Phase 2 / Phase 3 | Unknown | Ache Laboratorios Farmaceuticos S.A. | 307 | 2018-03-22 | 2020-09-03 |
Sleep Initiation and Maintenance Disorders (2)
Dyssomnias (2) · Mental Disorders (2) · Nervous System Diseases (2) · Sleep Disorders, Intrinsic (2) · Sleep Wake Disorders (2)
Ache Laboratorios Farmaceuticos S.A. (1) · Biolab Sanus Farmaceutica (1)
Brazil (1)
Mauro Crippa Jr. (1)